Cholesterol study points to new drugs

10 Sep 2012

1

Insight into how our bodies make cholesterol could lead to treatments with fewer side-effects than existing drugs.

Findings by Edinburgh scientists could pave the way for alternatives to commonly prescribed treatments, known as statins. These lower harmful cholesterol levels, but can cause liver and muscle damage.

High levels of cholesterol increase the risk of heart disease but, because cholesterol is vital to ensure the body's normal function, managing levels in the blood can be difficult.

This new study suggests a more effective approach, through a natural process

Statins curb cholesterol production - a complex series of chemical reactions that take place in the liver - by blocking production at one specific point in the process.

However, this stops the entire process and prevents the production of other molecules along the way, which have a role in making cell membranes, hormones and vitamin D.

Latest articles

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Global Chip Sales Expected to Hit $1 Trillion This Year, Industry Group Says

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Citi to Match Government Seed Funding for Children’s ‘Trump Accounts’

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

Huawei-Backed Aito Partners With UAE Dealer to Enter Middle East Market

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

AI is No Bubble: Nvidia Supplier Wistron Sees Order Surge Through 2027

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Tech Selloff Weighs on Asian Markets; Indonesia Slides After Moody’s Outlook Cut

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Amazon Plans $200 Billion AI Spending Surge; Shares Slide on Investor Jitters

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

Server CPU Shortages Grip China as AI Boom Strains Intel and AMD Supply Chains

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

OpenAI launches ‘Frontier’ AI agent platform in enterprise push

Toyota set for third straight quarterly profit drop as costs and tariffs weigh

Toyota set for third straight quarterly profit drop as costs and tariffs weigh